抗糖尿病药物和胃肠道疾病之间的因果关系:针对药物的门德尔随机化研究
Mingyan Ju1, Tingting Deng2, Xuemin Jia3
1College of Acupuncture and moxibustion, Shandong University of Traditional Chinese Medicine, Jinan, China.
Diabetology & metabolic syndrome
|June 25, 2024
概括
硫尿素可能有助于预防克罗恩病,GERD和慢性胃炎,但会增加胃的风险. 在这项研究中,其他抗糖尿病药物与胃肠道疾病没有因果关系.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 遗传学 遗传学 是一个
背景情况:
- 糖尿病性胃肠道疾病越来越普遍.
- 了解抗糖尿病药物和胃肠道疾病之间的因果关系对于患者护理和药物重用至关重要.
- 这项研究解决了与糖尿病相关的胃肠道并发症的日益增长的发病率.
研究的目的:
- 调查各种抗糖尿病药物与一系列胃肠道疾病之间的因果关系.
- 确定抗糖尿病药物对消化系统健康的潜在保护性或有害影响.
- 探索重新利用现有的抗糖尿病药物治疗胃肠道疾病的可能性.
主要方法:
- 使用了一个双样本的门德尔随机化 (TSMR) 设计.
- 与多种类型的抗糖尿病药物相关的遗传变异被分析为它们对胃肠道疾病的因果作用.
- 逆方差加权 (IVW) 是评估这些关联的主要方法.
主要成果:
- 硫尿素显示出对克罗恩病 (CD),胃食道逆流病 (GERD) 和慢性胃炎具有显著的保护作用.
- 相反,硫类尿素与患胃 (GU) 的风险增加有关.
- 在其他抗糖尿病药物 (如甲福明,GLP-1激动剂,SGLT2抑制剂,DPP-4抑制剂,胰岛素, thiazolidinediones,α-glucosidase抑制剂) 和研究的胃肠道疾病之间没有发现显著的因果关系.
结论:
- 硫尿素似乎具有双重效应,可以保护某些胃肠道疾病,同时增加其他疾病的风险.
- 目前的证据不支持通常使用的抗糖尿病药物 (除硫氨酸尿素) 在胃肠道疾病中起因作用.
- 需要进一步的研究来阐明糖尿病管理和胃肠道健康之间的复杂相互作用.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
169
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
169
Factors Influencing Drug Absorption: Disease States and Pharmacology
492
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
492
Oral Hypoglycemic Agents: Biguanides and Glitazones
188
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
188
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
203
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
203
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Dipeptidyl Peptidase 4 Inhibitors
180
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
180


